Company intelligence / Profile preview

Utilizer

Ownership: Private
Development stage: Other

Overview

Utilizer has developed an innovative point-of-care diagnostic tool for urinary tract infections that integrates miniaturized chromogenic bacterial cultivation with rapid antimicrobial susceptibility testing. The technology enables faster and more accurate diagnosis of UTIs at the point of care, supporting targeted antibiotic use and combating antimicrobial resistance. Clinical research demonstrates its accuracy is close to gold-standard urine culture tests[1][5].

Therapeutic areas: Infectious Diseases
Modalities: DeviceDigital bioassayBacterial culture-based diagnostics
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Utilizer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Utilizer.

Explore the full profile